CN116675729A - Application of alkali-resistant protein A variant in removal of IgG antibodies in sample - Google Patents

Application of alkali-resistant protein A variant in removal of IgG antibodies in sample Download PDF

Info

Publication number
CN116675729A
CN116675729A CN202310695184.7A CN202310695184A CN116675729A CN 116675729 A CN116675729 A CN 116675729A CN 202310695184 A CN202310695184 A CN 202310695184A CN 116675729 A CN116675729 A CN 116675729A
Authority
CN
China
Prior art keywords
protein
variant
alkali
seq
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310695184.7A
Other languages
Chinese (zh)
Inventor
王智
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemaisi Beijing Biotechnology Co ltd
Bailingke Lanzhou New Materials Co ltd
Original Assignee
Kemaisi Beijing Biotechnology Co ltd
Bailingke Lanzhou New Materials Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemaisi Beijing Biotechnology Co ltd, Bailingke Lanzhou New Materials Co ltd filed Critical Kemaisi Beijing Biotechnology Co ltd
Priority to CN202310695184.7A priority Critical patent/CN116675729A/en
Publication of CN116675729A publication Critical patent/CN116675729A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Protein A variants, particularly protein A variants having high alkali resistance and high IgG binding affinity, are disclosed. The application also discloses application of the protein A variant.

Description

Application of alkali-resistant protein A variant in removal of IgG antibodies in sample
The present application is a divisional application of chinese patent application No. 202111572524.4 filed on month 21 of 2021, which is incorporated herein by reference in its entirety.
Technical Field
The present application relates to protein a variants, in particular protein a variants having high alkali resistance. The application also relates to the use of the protein A variants.
Background
In recent years, antibody drugs have been rapidly developed. Half of the drugs on the top 10 forehead are antibody drugs on global sales in 2020. The purification step in the antibody drug manufacturing process typically employs classical three-step or two-step chromatography. Staphylococcus aureus protein A is a bacterial protein which is discovered in the last 70 th century and can be combined with the Fc end of multi-species antibodies, and since the discovery, the staphylococcus aureus protein A is always studied as an important antibody purification chromatography ligand, and is an affinity ligand which is relatively perfect in commercialization and relatively wide in application. The research shows that the unique specific adsorption capacity of a plurality of areas on the protein A ligand to the Fc segment of the antibody can be used for the specific capture of the antibody, and most of impurities in the cell fermentation broth can be removed by one-step process, and the purity can reach more than 98%. With the development of antibody drugs, affinity chromatography media for antibody capture have also been developed rapidly.
The selection of the affinity chromatography medium is closely related to the quality of the product. For example, early Protein a (Protein a) affinity chromatography ligands are severely shed and difficult to clean, and if these process related impurities cannot be removed well in subsequent processes, there is a risk of eliciting immune responses, which in turn presents a great challenge to drug quality. Thus, foreign filler manufacturers have long begun to strive to increase ligand stability, binding capacity, and base resistance of the media. For example, currently, the main stream protein A affinity chromatography media such as MabSelect SuRe of Cytiva corporation is alkali-resistant chromatography media, and can resist 0.1-0.5M NaOH cleaning, so that protein precipitates, hydrophobic proteins, nucleic acids, endotoxin, viruses and the like attached to the filler can be removed efficiently and at low cost. Ligand stability was also enhanced with ligand shedding <100ppm. The dynamic binding capacity reaches more than 30 g/L. At present, most domestic antibody drug manufacturing enterprises adopt imported protein A affinity chromatography media. These imported protein a affinity chromatography media are generally expensive, accounting for about 85% of the total chromatography media cost in downstream purification processes of antibody drugs, and suffer from various drawbacks that can be improved. For example, the basic frame microsphere of MabSelect SuRe is agarose with high crosslinking, has the advantages of excellent hydrophilicity and good biocompatibility, and is very suitable for the separation and purification of antibody biomacromolecules; but has the disadvantages that: firstly, the structure is softer, the particle size distribution is wider, and the problems of poor column filling repeatability, low mechanical strength and the like exist in the actual use process; secondly, mabSelect Sure is generally cleaned by using 0.1M NaOH in the bio-pharmaceuticals, and the alkali resistance is still different; thirdly, the dynamic loading of MabSelect Sure is more than 30g/L, and there is a gap in the loading required for large-scale high-expression antibody production. As another example, prosep Ultra Plus from Millipore corporation is also a widely used protein a affinity chromatography medium, the matrix is a glass bead structure with controllable pore channels, the physical stability is good, and the loading is high. However, the glass bead structure has a consistent defect that it is not tolerant of high concentration NaOH wash, thus limiting its use in large-scale biological samples.
Because of the high price and various shortcomings of imported fillers, it is necessary to develop protein a affinity fillers with high efficiency and low cost in domestic use.
Disclosure of Invention
Provided herein is the use of an alkali-resistant protein a variant in the removal of IgG antibodies in a sample, wherein the alkali-resistant protein a variant comprises
1) SEQ ID NO:1-3, 5-10; or (b)
2) And SEQ ID NO:1-3, 5-10, and an amino acid sequence having at least 90% sequence identity to the amino acid sequence set forth in any one of claims.
In some embodiments, the alkali-resistant protein A variant binds to IgG antibodies with a KD of no more than 1X 10 -6 M is not higher than 1×10 -7 M or not higher than 3X 10 -8 M。
In some embodiments, the IgG antibody is an IgG1 molecule.
In some embodiments, the alkali-resistant protein a variant has an amino acid sequence as set forth in SEQ ID NO: 1.
In some embodiments, the alkali-resistant protein a variant has an amino acid sequence as set forth in SEQ ID NO: 3.
In some embodiments, the alkali-resistant protein a variant has an amino acid sequence as set forth in SEQ ID NO: shown at 10.
In some embodiments, the alkali-resistant protein a variant is in the form of a fusion protein comprising 2, 3, 4, 5, or more of the alkali-resistant protein a variants connected in series.
In some embodiments, the sample is blood.
In some embodiments, the alkali-resistant protein a variant is coupled to agarose microspheres.
Drawings
FIG. 1 is a schematic structure of protein A. Where S is a signal sequence, E, D, B, A, C is five IgG binding domains, and the X and M sequences are associated with cell wall attachment. Also shown is the Z domain, which is a mutated version of the B domain, including the G29A mutation relative to the B domain.
FIG. 2 is a flow chart of the method for directed optimization of protein A variants of the present application.
FIG. 3 is a diagram showing the identity matrix between the target sequence and the initial sequence of the protein A variant obtained by the present application.
FIG. 4 is a pET28a (+) vector map for expression of a protein A variant.
FIG. 5 is an electrophoretogram of the purified protein A variant.
FIG. 6 shows the results of the determination of the dynamic load of the protein A variant of the present application.
Detailed Description
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
Protein a (SpA) is a cell wall protein from staphylococcus aureus (Staphylococcus aureus). Native protein a contains five highly homologous domains, E, D, A, B and C domains, respectively (fig. 1). Each domain is capable of binding to the Fc-segment of immunoglobulin G (IgG) of a human or other mammal, such as a mouse, pig, dog, cow, etc., which binding does not normally affect the ability of Fab fragments in IgG molecules to specifically bind to an antigen. Natural protein a is widely used for purification of antibody molecules after coupling to microspheres (e.g. agarose) or after being otherwise immobilized. Since the five domains of native protein a will have slightly different binding strengths to the same antibody molecule, elution conditions will be different, often requiring elution of the purified product at different pH or denaturant concentrations, resulting in complex procedures or inactivation of the antibody molecule due to the inability to withstand such conditions. Thus, researchers have, for example, employed genetic engineering techniques to engineer the protein a gene, using only one or a few specific domains in tandem, to provide recombinant protein a with desired binding affinity or other properties (e.g., alkali resistance).
"domain" refers to a spatially distinct, relatively independent, regional structure in a larger protein molecule. For smaller protein molecules, the domain is often equivalent to its tertiary structure. The domain may have a specific function, such as binding to a ligand (e.g., the B domain of protein a binds IgG), or enzymatic activity, etc. In this context, unless otherwise indicated, a domain may also refer to a polypeptide fragment or to the protein itself, which comprises only one domain.
"protein A variant" generally refers to a protein or protein domain having IgG binding capacity that differs in amino acid sequence from native protein A or a particular domain thereof, e.g., may include one or more amino acid mutations (e.g., substitutions, deletions, insertions, etc.) relative to native protein A. As used herein, "protein A variant" refers to a protein (or polypeptide fragment) of interest obtained by the inventors after directed optimization on the basis of protein A and other proteins, which differs significantly in amino acid sequence from native protein A or domains thereof, e.g., identity of not more than 85% after amino acid sequence alignment; in addition, it is alkali resistant and may or may not have IgG binding capacity.
"alkaline-resistant protein A variant" refers to a protein A variant that is resistant to alkaline treatment. "alkaline-resistant" as used herein refers to the ability of a protein A variant to remain bound to an IgG molecule for a period of time or number of times when it is exposed to an alkaline solution (e.g., 0.1, 0.2, 0.3, 0.4, or 0.5M NaOH solution). Preferably, the alkali-resistant protein a variant retains more than 50%, more than 60%, more than 70%, more than 80% or even more than 90% of its affinity to bind IgG molecules after 10 (e.g. 50, 100, 150 or even 180) contacts with an alkaline solution (e.g. 0.1 or 0.5M NaOH solution).
The "Z domain" is a domain that is engineered to also have IgG binding capacity from the B domain of native protein A. The Z domain includes a G29A mutation relative to domain B. This mutation allows the Z domain to be stable to certain chemical agents (e.g., CNBr, hydroxylamine, etc.) relative to the B domain and increases the ability to bind IgG. For more information on the Z domain, see the description of Nilsson B et al (A Synthetic IgG-Binding Domain Based on Staphylococcal Protein A. Protein Eng.1987,1 (2): 107-113, which is incorporated herein by reference in its entirety).
When referring to amino acid or nucleotide sequences, the term "sequence identity (Sequence identity)" (also referred to as "sequence identity") refers to the amount of degree of identity between two amino acid or nucleotide sequences (e.g., a query sequence and a reference sequence), typically expressed as a percentage. Typically, sequence alignment (alignment) is performed and gaps (gaps), if any, introduced prior to calculating the percent identity between two amino acid or nucleotide sequences. If at a certain alignment the amino acid residues or bases in the two sequences are identical, then the two sequences are considered to be identical or matched at that position; amino acid residues or bases in the two sequences differ, and are considered to be inconsistent or mismatched at that position. In some algorithms, the number of matching positions is divided by the total number of positions in the alignment window to obtain sequence identity. In other algorithms, the number of gaps and/or the gap length are also considered. For the purposes of the present application, the disclosed alignment software BLAST (found in the webpage ncbi.nlm.nih.gov) can be used to obtain optimal sequence alignment by using default settings and calculate sequence identity between two amino acid or nucleotide sequences.
In some embodiments, a protein a variant provided herein can include a sequence that hybridizes to SEQ ID NO:1-3, 5-10, or a sequence having at least 90% sequence identity (e.g., at least 95%, at least 98%, at least 99%, or even 100% sequence identity).
In some embodiments, the DNA sequences encoding protein a variants provided herein may include sequences that match SEQ ID NOs: 11-13, 15-20 (e.g., at least 95%, at least 98%, at least 99% or even 100% sequence identity).
It will be appreciated by those skilled in the art that variants of the protein a variants provided herein may be obtained by substitution (e.g., conservative substitution), deletion, addition, and validation or screening of a few amino acids for the ability of the resulting product to bind IgG and/or to base, based on the particular amino acid sequences provided herein, and are intended to be within the scope of the present application. Similarly, based on the specific nucleotide sequences provided herein, one of skill in the art can obtain other nucleotide sequences that are functionally substantially identical to the nucleotide sequences provided herein by substituting (e.g., synonymously mutating), deleting, adding, and verifying or screening for their expression of the product of interest and the ability of the product of interest to bind to IgG and/or to base resistance, and are also included within the scope of the present application.
Protein a variants provided herein may be part of other proteins. In one embodiment, provided herein are fusion proteins comprising one or more protein a variants (e.g., 1, 2, 3, 4, 5, 6, or even more). The protein A variants of the fusion protein may be linked in tandem by a linker molecule (e.g., an amino acid short sequence). Preferably, the linker molecule is also alkali resistant, such a linker molecule being described for example in PCT publication WO 03080655. In another embodiment, provided herein are fusion proteins comprising one or more protein a variants (e.g., 1, 2, 3, 4, 5, 6, or even more) and at least one other domain that also has IgG binding capacity. Such other domains are, for example, domains E, D, A, B and C of protein a, or the "Z domain" described above. In addition, it is also contemplated that the protein a variants provided herein may be linked to a signal peptide or purification tag that is convenient to prepare, such as a histidine tag, strep II tag, and the like. These fusion proteins can be conveniently obtained by genetic engineering techniques by those skilled in the art, based on the amino acid and nucleotide sequences provided herein for protein a variants.
Protein a variants provided herein all have substantially IgG (e.g., igG 1) binding capacity (except # 4), even part of the protein a variants (# 1, #3, and # 10) have higher IgG binding affinity than the Z domain used as a control (see example 2). Accordingly, these protein a variants may have higher dynamic loading or purification capacity when used to separate IgG from IgG-containing cellular components (e.g., cell culture supernatant).
Meanwhile, some of the protein a variants (# 1, #3, and # 10) provided herein have good alkali resistance, wherein the alkali resistance of the protein a variant #10 is even better than that of Mabselect SuRe (see example 4). The protein A variants can endure NaOH cleaning up to 0.5M, and can meet the requirements of repeated sterilization, heat source removal and the like of equipment in the pharmaceutical process.
In addition, the partially codon-optimized protein A variant coding sequences (# 1, #2, #3, and # 10) provided herein can increase the expression of the protein A variant in a host cell (e.g., E.coli BL 21), for example, by 30% over the coding sequence of the Z domain used as a control.
As described previously, the protein a variants provided herein (as well as fusion proteins comprising the protein a variants) can be used for IgG purification. In addition, in some cases, it may be useful to remove IgG molecules from certain samples (e.g., blood) to obtain samples that are free of IgG molecules. It is also contemplated that the protein a variants provided herein (and fusion proteins comprising the protein a variants) can be used in immunoassays, e.g., the protein a variants can be labeled with a tracer (e.g., fluorescein, enzyme, colloidal gold, ferritin) in place of a second antibody for antigen detection.
The application is further described below by means of specific examples.
Example 1 Directional optimization method of alkali-resistant protein A variants
Aiming at the protein function optimization target for improving alkali resistance and improving the binding capacity with IgG, the application obtains the protein A variant with directional optimization through bioinformatics and convolutional neural network.
The specific technical scheme of the method can comprise the following steps (see fig. 2):
step 1: the E, D, C, B and A domains of protein A and the Z domain sequence were used as initial sequences for the directed optimization, and the crystal structures of the corresponding sequences were obtained from the RCSB-PDB database, with the structure of the A domain being obtained by the homology modeling method.
Step 2: the initial sequences were cross aligned and subjected to structural overlapping cluster analysis of amino acid residues.
Step 3: according to the sequence identity and the structure matching result of amino acid residues, the sequence is divided into a framework region and a variable region, wherein the framework region serves as a conserved sequence, the variable region serves as a fragmented sequence, and then the sequence of the variable region is split into three types of short sequences comprising single amino acid, double amino acid and three amino acid.
The framework region sequence base amino acids comprise:
Q/AFY/L/PNL/QRN/FIQSL/DPS/S/L/EA/KLN/QAPK。
the variable region sequence base amino acids comprise:
QAVI/QDA/NA/NKQ/FH/ND/KE/DEA/QH/SNA/EQ/IV/HN/LM/TN/EA/EDA/AG/KR/D H/VQ/LAKT/EN/ILV/GAS/KQ/DE/AS。
step 4: by means of random sequence growth and combination, the short sequences of assembled fragment areas are combined on the basis of the framework areas, and a potential sequence library containing random sequences is established, wherein the sequence length in the library is 58 amino acids, and the library has the identity (50% < identity < 85%) meeting certain conditions with the E, D, C, B and A domains and Z domain sequences of protein A.
Step 5: protein A sequences with alkali resistance and IgG binding capacity are obtained through literature investigation, primary structure molecular descriptors are calculated, the primary structure molecular descriptors are used as training sets after normalization treatment, convolutional neural networks comprising an input layer, a hidden layer and an output layer are pretrained, the hidden layer comprises 4 convolutional layers and 2 pooling layers, and the output layer is a dense connecting layer.
Step 6: and calculating a primary structure molecular descriptor for sequences in a potential sequence library, performing normalization processing, predicting by using a model trained in the previous step, selecting the first 10 sequences with high alkali resistance and high IgG binding capacity according to a predicted value, and performing further experimental verification.
The target sequence obtained by the method is as follows:
>T_SEQAA-1(SEQ ID NO：1)
IDNKFNEEQQAAFYEVLHMPNLNAEQRNGFIQSLKDDPSQSTNLLAEAQKLNEAQAPK
>T_SEQAA-2(SEQ ID NO：2)
QDNQFNKEQQNAFYQILHLPNLNAEQRNAFIQSLRHDPSQSLNLLGEAQKLNDSQAPK
>T_SEQAA-3(SEQ ID NO：3)
AQNKFDKEQQNAFYQILHMPNLTADQRNGFIQSLKDDPSQSANVLAEAQKLNDAQAPK
>T_SEQAA-4(SEQ ID NO：4)
AQNKHNKEHQNAFYQILHLPNLNEEQRNGFIQSLKDDPSVSANILGEAKKLNESQAPK
>T_SEQAA-5(SEQ ID NO：5)
QQNKHDEAQQSAFYEVLHMPNLTEEQRNGFIQSLKDDPSQSLELLGEAQKLNDSQAPK
>T_SEQAA-6(SEQ ID NO：6)
AAAQFNEEQQNAFYEILHMPNLTEAQRNAFIQSLKDDPSQSTNVLGEAQKLNDSQAPK
>T_SEQAA-7(SEQ ID NO：7)
QDNKFDEDQQSAFYQILHMPNLTEDQRNGFIQSLKHDPSVSANLLSEAQKLNESQAPK
>T_SEQAA-8(SEQ ID NO：8)
QDANFDKAHQSAFYEVLHLPNLNEEQRNAFIQSLKDDPSQSKNVLAEAQKLNDAQAPK
>T_SEQAA-9(SEQ ID NO：9)
IDNKFNKAQQNAFYEVLNMPNLTAAQRNGFIQSLRDDPSVSTELLGEAKKLNESQAPK
>T_SEQAA-10(SEQ ID NO：10)
QDNQHDEAQQAAFYEILNLPNLNEEQRNGFIQSLRHDPSQSAEILSEAKKLNESQAPK
the initial sequence of the method is as follows:
SEQAA_Parentil (Z domain) (SEQ ID NO: 21)
VDNKFNKEQQNAFYEILHLPNLNEEQRNAFIQSLKDDPSQSANLLAEAKKLNDAQA PK
The identity matrix between the target sequence and the initial sequence obtained by the method is shown in figure 3.
EXAMPLE 2 expression and purification of candidate protein A variants
Ten amino acid sequences and Z domain sequences from the T_SEQAA-1 to T_SEQAA-10 are optimized by using dominant codons of escherichia coli, and the corresponding DNA coding sequences are obtained as follows.
T-SEQDNA-1(SEQ ID NO：11)
ATTGATAACAAATTTAACGAAGAACAGCAGGCGGCGTTTTATGAAGTGCTGCAT
ATGCCGAACCTGAACGCGGAACAGCGTAACGGCTTTATTCAGAGCCTGAAAGAT
GATCCGAGCCAGAGCACCAACCTGCTGGCGGAAGCGCAGAAACTGAACGAAGC
GCAGGCGCCGAAA
T_SEQDNA-2(SEQ ID NO：12)
CAGGATAACCAGTTTAACAAAGAACAGCAGAACGCGTTTTATCAGATTCTGCAT
CTGCCGAACCTGAACGCGGAACAGCGTAACGCGTTTATTCAGAGCCTGCGTCAT
GATCCGAGCCAGAGCCTGAACCTGCTGGGCGAAGCGCAGAAACTGAACGATAG
CCAGGCGCCGAAA
T_SEQDNA-3(SEQ ID NO：13)
GCGCAGAACAAATTTGATAAAGAACAGCAGAACGCGTTTTATCAGATTCTGCAT
ATGCCGAACCTGACCGCGGATCAGCGTAACGGCTTTATTCAGAGCCTGAAAGAT
GATCCGAGCCAGAGCGCGAACGTGCTGGCGGAAGCGCAGAAACTGAACGATGC
GCAGGCGCCGAAA
T_SEQDNA-4(SEQ ID NO：14)
GCGCAGAACAAACATAACAAAGAACATCAGAACGCGTTTTATCAGATTCTGCAT
CTGCCGAACCTGAACGAAGAACAGCGTAACGGCTTTATTCAGAGCCTGAAAGAT
GATCCGAGCGTGAGCGCGAACATTCTGGGCGAAGCGAAAAAACTGAACGAAAG
CCAGGCGCCGAAA
T_SEQDNA-5(SEQ ID NO：15)
CAGCAGAACAAACATGATGAAGCGCAGCAGAGCGCGTTTTATGAAGTGCTGCAT
ATGCCGAACCTGACCGAAGAACAGCGTAACGGCTTTATTCAGAGCCTGAAAGAT
GATCCGAGCCAGAGCCTGGAACTGCTGGGCGAAGCGCAGAAACTGAACGATAG
CCAGGCGCCGAAA
T_SEQDNA-6(SEQ ID NO：16)
GCGGCGGCGCAGTTTAACGAAGAACAGCAGAACGCGTTTTATGAAATTCTGCAT
ATGCCGAACCTGACCGAAGCGCAGCGTAACGCGTTTATTCAGAGCCTGAAAGAT
GATCCGAGCCAGAGCACCAACGTGCTGGGCGAAGCGCAGAAACTGAACGATAG
CCAGGCGCCGAAA
T_SEQDNA-7(SEQ ID NO：17)
CAGGATAACAAATTTGATGAAGATCAGCAGAGCGCGTTTTATCAGATTCTGCAT
ATGCCGAACCTGACCGAAGATCAGCGTAACGGCTTTATTCAGAGCCTGAAACAT
GATCCGAGCGTGAGCGCGAACCTGCTGAGCGAAGCGCAGAAACTGAACGAAAG
CCAGGCGCCGAAA
T_SEQDNA-8(SEQ ID NO：18)
CAGGATGCGAACTTTGATAAAGCGCATCAGAGCGCGTTTTATGAAGTGCTGCAT
CTGCCGAACCTGAACGAAGAACAGCGTAACGCGTTTATTCAGAGCCTGAAAGAT
GATCCGAGCCAGAGCAAAAACGTGCTGGCGGAAGCGCAGAAACTGAACGATGC
GCAGGCGCCGAAA
T_SEQDNA-9(SEQ ID NO：19)
ATTGATAACAAATTTAACAAAGCGCAGCAGAACGCGTTTTATGAAGTGCTGAAC
ATGCCGAACCTGACCGCGGCGCAGCGTAACGGCTTTATTCAGAGCCTGCGTGAT
GATCCGAGCGTGAGCACCGAACTGCTGGGCGAAGCGAAAAAACTGAACGAAAG
CCAGGCGCCGAAA
T_SEQDNA-10(SEQ ID NO：20)
CAGGATAACCAGCATGATGAAGCGCAGCAGGCGGCGTTTTATGAAATTCTGAAC
CTGCCGAACCTGAACGAAGAACAGCGTAACGGCTTTATTCAGAGCCTGCGTCAT
GATCCGAGCCAGAGCGCGGAAATTCTGAGCGAAGCGAAAAAACTGAACGAAAG
CCAGGCGCCGAAA
SEQDNA-Parentil (Z domain) (SEQ ID NO: 22)
GTGGATAACAAATTTAACAAAGAACAGCAGAACGCGTTTTATGAAATTCTGCAT
CTGCCGAACCTGAACGAAGAACAGCGTAACGCGTTTATTCAGAGCCTGAAAGAT
GATCCGAGCCAGAGCGCGAACCTGCTGGCGGAAGCGAAAAAACTGAACGATGC
GCAGGCGCCGAAA
The 10 DNA sequences and the DNA sequence of the Z domain were inserted into pET28a (+) vector (FIG. 4) using BamHI and EcoRI at the 5 'and 3' ends, respectively, and then transformed into BL 21-expressing bacteria by heat shock of competent bacteria, inoculated onto LB plates for overnight culture, and single colonies were picked up and shake-cultured in 3mL LB medium at 37℃for 18 hours. 3mL of the bacterial liquid was further cultured by amplification to 20mL (OD 600)<0.4). Taking out 10mL of bacterial liquid, adding glycerol to 30% (v/v) for freezing and preserving seeds. The remaining 10mL was added to 1L LB medium (1:100) and expanded to OD600 = 0.6-0.8 (-2 hours), IPTG was added to a final concentration of 0.5mM and cooled to 16 ℃ overnight to induce protein expression. After 24 hours of overnight culture, the cells were collected by centrifugation. The cell pellet was resuspended in lysis buffer (50 mm nahpo4, ph= 8,0.3NaCl,Dnase I,Protease inhibitor). After ultrasonic sterilization, mgCl is added 2 The supernatant was collected by centrifugation at a final concentration of 75mM and stirred at 4℃for 3 hours. The 10 candidate protein A variants and the control Z domain were purified by Ni-NTA to a purity of 95% or more, and SDS-PAGE results shown in FIG. 5, and the protein variants and Z domain were approximately 7kDa in size. Through data analysis, the expression level of variant #1 (corresponding to T_SEQAA-1 and so on) is 30% or more higher than that of coding DNA of Z domain, while the expression level of variant #4, #5, #6, #7, #8, #9 is inferior to that of coding DNA of Z domain. The resulting protein a variant proteins and Z were tested for affinity for human IgG1 antibodies using Fortebio oct, the results are shown in table 1.
Table 1 affinity assay results for protein a variants and Z domain controls binding to IgG1
Protein A variant numbering Kon(1/Ms) Koff(1/s) KD(M)
Z 1.4E5 3.6E-3 2.6E-8
T_SEQAA-1 1E5 2.2E-3 2.2E-8
T_SEQAA-2 1.3E4 1.1E-2 8.4E-7
T_SEQAA-3 1.2E5 1.3E-3 1.1E-8
T_SEQAA-4 ND ND N/A
T_SEQAA-5 1.8E4 3.3E-2 1.8E-6
T_SEQAA-6 1.2E4 5.6E-3 2.1E-7
T_SEQAA-7 3.8E3 6.6E-4 1.7E-7
T_SEQAA-8 9.5E3 1.5E-3 1.6E-7
T_SEQAA-9 8E2 2.8E-4 3.5E-7
T_SEQAA-10 2.1E5 4E-3 1.9E-8
ND: no N/a detected: is not suitable for
As can be seen from table 1, except for #4, the other 9 protein a variants all had detectable binding affinity for the IgG1 antibody, with #1, #3, #10 binding affinity to the IgG1 antibody even better than the control Z domain.
Example 3 conjugation of candidate protein A variants and microspheres
In the embodiment, agarose microspheres with high uniformity of particle size and good mechanical strength are selected as a base frame, and candidate protein A variants (No. 1, no. 3 and No. 10) with affinity similar to that of a Z structural domain are coupled.
The coupling procedure is briefly as follows.
Step 1: weighing 5mL of the epoxy-activated microspheres, and cleaning the microspheres for 2 times by using 10mL 0.1M PB,pH 8.6 buffer solution;
step 2: adding 3mg of candidate protein a variant per ml of filler;
step 3: reacting for 1 hour at 30+/-1 ℃;
step 4: washing the gel with 20ml of water each time for 2 times, collecting the washing liquid to measure the protein concentration (OD 280), and calculating the protein A variant content of the coupling;
step 5: washing the gel with 20ml of water for 5 times;
step 6: washing with 5ml of 20% ethanol for 2 times;
step 7:20% ethanol 3mL, 2-8deg.C.
Example 4 determination of alkali resistance and dynamic Loading of affinity chromatography media
The protein A affinity chromatography medium prepared above was used to fill a Hitrip 1mL column and washed with equilibration solution. The alkaline resistance and dynamic binding capacity of the mutant-coupled affinity medium to be tested were tested using MabSelect SuRe (Cytiva) as reference. The AKTA purifier protein purifier was equilibrated with purified water prior to use, and the baseline was zeroed after equilibration. 20mM PBS,150mM NaCl,pH7.0 buffer and 50mM Gly, pH3.0 buffer were used as the equilibrium phase and the elution phase, respectively, and the system pump was equilibrated with the equilibrium phase. The column was connected to AKTA pulsifer, taking care to prevent air bubbles from entering during connection, the pump was run at a flow rate during connection, the joint portion was fully wetted with mobile phase, the upper end of the column was also filled with mobile phase, and then connected. The column was washed sequentially with 50mM Gly, pH3.0 and 20mM PBS,150mM NaCl,pH7.0 each at 10CV to baseline equilibrium. The antibody cell culture supernatant (1 mg/mL), about 50mL per column, was initially fed at 0.25mL/min, and the antibody was eluted with an elution phase, and the column dynamic binding capacity was calculated by analyzing the total amount of antibody elution. The column was then subjected to CIP with 0.1M NaOH and 0.5M NaOH, respectively. The above steps are repeated for 180 cycles. And detecting and analyzing dynamic load change conditions. The results are shown in FIG. 6. All three variants (# 1, #3 and # 10) showed superior alkali resistance, and were able to withstand multiple CIP treatments with NaOH up to 0.5M. They are also capable of reaching substantially more than 80% of the initial loading when recycled 100 times and also do not exhibit a rapid drop in dynamic loading when recycled 180 times. In particular, the #10 variant exhibited higher dynamic loading than Mabselect SuRe throughout the test, whether treated with 0.1M or 0.5M NaOH.
The MabSelect SuRe control currently performs well in terms of affinity and alkali resistance for IgG, whereas the novel protein A variants provided by the present application mimic or are better than it does in terms of affinity and alkali resistance, and may provide more options for the user. Given the great advantage (more than 30% higher) of protein a variants #1, #2, #3 and #10 in terms of expression compared to the wild-type Z domain, there is also a cost advantage in expressing these protein a variants by the coding DNA sequences provided herein.

Claims (9)

1. Use of an alkali-resistant protein a variant for removing IgG antibodies from a sample, wherein the alkali-resistant protein a variant comprises
1) SEQ ID NO:1-3, 5-10; or (b)
2) And SEQ ID NO:1-3, 5-10, and an amino acid sequence having at least 90% sequence identity to the amino acid sequence set forth in any one of claims.
2. The use according to claim 1, wherein the alkali-resistant protein A variant binds to the IgG antibody with a KD of not more than 1X 10 -6 M is not higher than 1×10 -7 M or not higher than 3X 10 -8 M。
3. The use of claim 2, wherein the IgG antibody is an IgG1 molecule.
4. Use according to any one of claims 1-3, wherein the alkali-resistant protein a variant has the amino acid sequence set forth in SEQ ID NO: 1.
5. Use according to any one of claims 1-3, wherein the alkali-resistant protein a variant has the amino acid sequence set forth in SEQ ID NO: 3.
6. Use according to any one of claims 1-3, wherein the alkali-resistant protein a variant has the amino acid sequence set forth in SEQ ID NO: shown at 10.
7. The use of any one of claims 1-3, wherein the alkali-resistant protein a variant is in the form of a fusion protein comprising 2, 3, 4, 5 or more of the alkali-resistant protein a variants connected in series.
8. The use of any one of claims 1-3, wherein the sample is blood.
9. The use of any one of claims 1-3, wherein the alkali-resistant protein a variant is coupled to agarose microspheres.
CN202310695184.7A 2021-12-21 2021-12-21 Application of alkali-resistant protein A variant in removal of IgG antibodies in sample Pending CN116675729A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310695184.7A CN116675729A (en) 2021-12-21 2021-12-21 Application of alkali-resistant protein A variant in removal of IgG antibodies in sample

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202310695184.7A CN116675729A (en) 2021-12-21 2021-12-21 Application of alkali-resistant protein A variant in removal of IgG antibodies in sample
CN202111572524.4A CN114591407B (en) 2021-12-21 2021-12-21 Alkali-resistant protein A variants and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202111572524.4A Division CN114591407B (en) 2021-12-21 2021-12-21 Alkali-resistant protein A variants and uses thereof

Publications (1)

Publication Number Publication Date
CN116675729A true CN116675729A (en) 2023-09-01

Family

ID=81803626

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202310688066.3A Pending CN116925197A (en) 2021-12-21 2021-12-21 Application of alkali-resistant protein A variant in purification of IgG antibody
CN202310695184.7A Pending CN116675729A (en) 2021-12-21 2021-12-21 Application of alkali-resistant protein A variant in removal of IgG antibodies in sample
CN202111572524.4A Active CN114591407B (en) 2021-12-21 2021-12-21 Alkali-resistant protein A variants and uses thereof
CN202310688624.6A Pending CN116679071A (en) 2021-12-21 2021-12-21 Immunoassay method

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310688066.3A Pending CN116925197A (en) 2021-12-21 2021-12-21 Application of alkali-resistant protein A variant in purification of IgG antibody

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202111572524.4A Active CN114591407B (en) 2021-12-21 2021-12-21 Alkali-resistant protein A variants and uses thereof
CN202310688624.6A Pending CN116679071A (en) 2021-12-21 2021-12-21 Immunoassay method

Country Status (1)

Country Link
CN (4) CN116925197A (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2705334C (en) * 2007-11-12 2018-04-17 Novozymes A/S Dual affinity polypeptides for purification
CN104059133B (en) * 2013-03-18 2019-03-15 南京金斯瑞生物科技有限公司 The albumin A with high alkaline-resisting characteristic of one kind mutation and its application
WO2018029158A1 (en) * 2016-08-11 2018-02-15 Repligen Corporation Alkaline stable fc—binding proteins for affinity chromatography
JP2020509076A (en) * 2017-01-04 2020-03-26 ナンジンジンスールイ サイエンス アンド テクノロジー バイオロジー コーポレイションＮａｎｊｉｎｇｊｉｎｓｉｒｕｉ Ｓｃｉｅｎｃｅ ＆ Ｔｅｃｈｎｏｌｏｇｙ Ｂｉｏｌｏｇｙ Ｃｏｒｐ． High load and alkali resistant protein A magnetic beads and method of using the same

Also Published As

Publication number Publication date
CN116679071A (en) 2023-09-01
CN114591407B (en) 2023-07-04
CN116925197A (en) 2023-10-24
CN114591407A (en) 2022-06-07

Similar Documents

Publication Publication Date Title
JP6862008B2 (en) Mutant immunoglobulin binding polypeptide
US20210162319A1 (en) Mutated Immunoglobulin-Binding Polypeptides
US10464972B2 (en) Multimer of mutant protein A and methods of using same
US11136357B2 (en) Modified kappa light chain-binding polypeptides
JP6724000B2 (en) Mutant immunoglobulin binding polypeptide
CN113512099B (en) Staphylococcus protein A, purification preparation method and application thereof
JP2019517789A (en) Mutant immunoglobulin binding polypeptide
JP2022519808A (en) Immunoglobulin-binding protein for affinity purification
CN116874571A (en) Mutant protein A domain C and uses thereof
CN102676562B (en) Preparation method and application of fusion protein with broad spectrum adsorption capacity to antibodies
KR20220002325A (en) A method for isolating an antibody or antibody fragment lacking an Fc region capable of binding protein A
CN114591407B (en) Alkali-resistant protein A variants and uses thereof
EP3630793A1 (en) A recombinant protein
JP4481260B2 (en) Antibody binding peptide
CN104945488B (en) Polypeptide with immunoglobulin binding capacity
CN107849095A (en) The antibody-binding protein that antibody binding capacity in acid pH range reduces
CN116670150A (en) Immunoglobulin binding polypeptides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination